Jan 13 (Reuters) - Eli Lilly ( LLY ) said on Monday it

has sued two medical spas for selling unapproved products

claiming to contain tirzepatide, the main ingredient in its

popular weight-loss medicine Zepbound.

The new lawsuits name Thrive Health and Wellness LLC and

Valhalla Vitality LLC. Lilly said the companies were selling

unapproved drugs and making false claims about efficacy, purity

or safety.

Thrive Health and Valhalla Vitality both sell products that

they say contain tirzepatide, according to the filings.

The complaint against Thrive was filed in the district court

of Colorado and the complaint against Valhalla was filed in the

Eastern District of New York.

The Indianapolis-based drugmaker has already sued more than

two dozen medical spas, wellness centers and compounding

pharmacies for selling products claiming to contain tirzepatide,

which is also approved to treat type 2 diabetes under the brand

name Mounjaro.